Document is current
Any future updates will be listed below
-
Authors
Falcó-Roget, Anna https://orcid.org/0009-0003-1774-679X
Raiola, Anna Maria
Balletto, Elisa https://orcid.org/0000-0001-9716-5538
Varaldo, Riccardo
Gambella, Massimiliano https://orcid.org/0000-0002-7896-4198
Lanino, Emanuele https://orcid.org/0009-0000-0676-0201
Sepulcri, Chiara
Ghiso, Anna
Giannoni, Livia
Bregante, Stefania
Laudisi, Antonella
Passannante, Monica
Bassetti, Matteo
Angelucci, Emanuele https://orcid.org/0000-0002-6512-6080
Mikulska, Malgorzata https://orcid.org/0000-0002-5535-4602
- License Information
-
More Information
Article History
Received: 3 June 2024
Revised: 19 November 2024
Accepted: 29 November 2024
First Online: 11 December 2024
Competing interests
: We declare that the research was conducted in the absence of any commercial or financial relationships that could be regarded as a potential conflict of interest. EA has served as the Chair of the Data Monitoring Committee (DMC) for Vertex Pharmaceuticals Incorporated and Celgene (BSM), and as a DMC member for Vifor Pharma. Additionally, EA has been a member of the advisory boards for Novartis, Menarini Stemline, Glaxo, GILEAD, and Regeneron, has served as consultant for Menarini Stemline and as speaker for GILEAD-Kite and Novartis. All other authors declare no competing interests.
